Phase 3 N=302 Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Overall Survival — 191.0; 163.0 days — p== 0.3287
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=462 The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
Non-squamous, Non-Small Cell Lung Cancer
Primary: Time on Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) — 9.89; 27.7 Months
Phase 3 N=722 Evaluation of N1539 Following Major Surgery
Pain, Post-operative
Primary: Number of Subjects With Adverse Events — 339; 119 Participants
Phase 2 N=205 Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)
Non-Alcoholic Fatty Liver Disease · Non-Alcoholic Fatty Liver · Non-Alcoholic Steatohepatitis
Primary: Change in Hepatic Fat Fraction [%] Between of Vitamin E and DHA EE vs Placebo — -6.8; -8.2 Percentage of liver fat
Phase 2 N=209 Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use
Nicotine Dependence
Primary: Mean Number of Conventional Cigarettes Smoked During Each Switch Week — 3.2; 3.2; 5.8; 3.1 Cigarettes per day
N/A N=63 The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Primary: Proportion of Patients With Successful Outcomes (<5-point Decrease in FACT-NTX From Baseline) — 0.45; 0.59; 0.52 Proportion of Patients
N/A N=59 Improving Self-Efficacy Through a Telenovela: Feasibility Study
Healthy
Primary: Change in HFCG Anxiety Before and After NOVELA as Assessed by the Generalized Anxiety Disorder 7-item Scale — 8.63; 7.67 score on a scale
Phase 3 N=194 Evaluation of Preoperative N1539 in Total Knee Arthroplasty
Pain, Postoperative
Primary: Opioid Use Hour 0-24 — 18.94; 27.73 mg morphine equivalent
Phase 2 N=5 Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells
Primary: Number of Participants Experiencing Adverse Events Incidence With of Salicylate + Venetoclax + Decitabine — 1 Participants
Phase 2 N=120 The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure
Acute Decompensated Heart Failure
Primary: Change in E/Ea Ratio — -4.55; -1.55; -3.16; -1.08 Unitless ratio — p=0.029
N/A N=26 Outcomes of Esophageal Self Dilation for Benign Refractory Esophageal Stricture Management
Esophageal Dilation · Refractory Benign Esophageal Stricture
Primary: Number of Endoscopic Interventions — 12; 11; 12; 7 endoscopies
Phase 3 N=159 A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A
Factor VIII Deficiency
Primary: Estimated Annualized Bleeding Rate (ABR) in Arm A: Prophylaxis — 0.71 episodes per participant per year
N/A N=38 SPIRIT for Persons With Dementia and Complex Multimorbidity
End Stage Renal Disease
Primary: Dyad Congruence — 1; 5; 8; 5 Dyads
Phase 2 N=50 OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia
Primary: Number of Participants With a Response — 0; 8; 1; 2 Participants
Phase 3 N=291 A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -2.03; -1.08 Percentage of HbA1c — p=<0.001